You are here

  • Home
  • Archive
  • Volume 70, Issue 10
  • Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Article info

Article menu
Download PDFPDF
Inflammatory bowel disease
Original research
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD

Authors

  • Nicholas A Kennedy Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Simeng Lin Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • James R Goodhand Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Neil Chanchlani Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Benjamin Hamilton Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Claire Bewshea Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Rachel Nice Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK PubMed articlesGoogle scholar articles
  • Desmond Chee Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • JR Fraser Cummings Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton, UK PubMed articlesGoogle scholar articles
  • Aileen Fraser Gastroenterology, University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK PubMed articlesGoogle scholar articles
  • Peter M Irving Gastroenterology, Guy's and St Thomas' Hospitals NHS Trust, London, UK School of Immunology & Microbial Sciences, King's College London, London, UK PubMed articlesGoogle scholar articles
  • Nikolaos Kamperidis Gastroenterology, St Marks Hospital and Academic Institute, London, UK, London, UK PubMed articlesGoogle scholar articles
  • Klaartje B Kok Gastroenterology, Barts and The London NHS Trust, London, UK Centre for Immunobiology, Blizard Institute, Barts and The London School of Medicine and Dentistry Blizard Institute, London, UK PubMed articlesGoogle scholar articles
  • Christopher Andrew Lamb Translational & Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK Gastroenterology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK PubMed articlesGoogle scholar articles
  • Jonathan Macdonald Gastroenterology, Queen Elizabeth University Hospital, NHS Greater Glasgow and Clyde, Glasgow, UK School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK PubMed articlesGoogle scholar articles
  • Shameer Mehta Gastroenterology, University College London Hospitals NHS Foundation Trust, London, UK PubMed articlesGoogle scholar articles
  • Richard CG Pollok Gastroenterology, St George's University Hospitals NHS Foundation Trust, London, UK Institute for Infection & Immunity, University of London St George's, London, UK PubMed articlesGoogle scholar articles
  • Tim Raine Gastroenterology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK PubMed articlesGoogle scholar articles
  • Philip J Smith Gastroenterology, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK PubMed articlesGoogle scholar articles
  • Ajay Mark Verma Gastroenterology, Kettering General Hospital NHS Foundation Trust, Kettering, UK PubMed articlesGoogle scholar articles
  • Simon Jochum Roche Diagnostics GmbH, Mannheim, Baden-Württemberg, Germany PubMed articlesGoogle scholar articles
  • Timothy J McDonald Biochemistry, Exeter Clinical Laboratory International, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK PubMed articlesGoogle scholar articles
  • Shaji Sebastian IBD Unit - Gastroenterology, Hull University Teaching Hospitals NHS Trust, Hull, UK Hull York Medical School, University of Hull, Hull, UK PubMed articlesGoogle scholar articles
  • Charlie W Lees Gastroenterology, Western General Hospital, Edinburgh, Edinburgh, UK The University of Edinburgh Centre for Genomic and Experimental Medicine, Edinburgh, UK PubMed articlesGoogle scholar articles
  • Nick Powell Metabolism, Digestion and Reproduction, Imperial College London, London, UK Gastroenterology, Imperial College Healthcare NHS Trust, London, UK PubMed articlesGoogle scholar articles
  • Tariq Ahmad Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group, University of Exeter, Exeter, UK PubMed articlesGoogle scholar articles
  • Contributors to the CLARITY IBD study
    Google scholar articles
  1. Correspondence to Dr Tariq Ahmad, Gastroenterology, Royal Devon and Exeter NHS Foundation Trust, Exeter, UK; tariq.ahmad1{at}nhs.net
View Full Text

Citation

Kennedy NA, Lin S, Goodhand JR Contributors to the CLARITY IBD study, et al
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD
Gut 2021;70:1884-1893.

Publication history

  • Received March 29, 2021
  • Revised April 8, 2021
  • Accepted April 10, 2021
  • First published April 26, 2021.
Online issue publication 
January 10, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage